Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Remon Abu Elyazeed"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)
Combined measles-mumps-rubella (MMR) vaccines produced by GSK (GSK-MMR) and Merck (Merck-MMR) have demonstrated effectiveness and an acceptable safety profile, as documented over decades of post-licensure use in various regions worldwide. In the Unit
Externí odkaz:
https://doaj.org/article/fabab714a90042afb694983316b19302
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 3, Pp 872-879 (2021)
A systematic literature review of Medline and Embase databases was conducted to describe rotavirus (RV) vaccine coverage for a complete series, timing of receipt of all doses in the series, and predictors of RV vaccination coverage in the US for two
Externí odkaz:
https://doaj.org/article/9b1fd2983f79445fa5acafad0f754b8b
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 4, Pp 809-821 (2019)
Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis and Haemophilus influenzae type b vaccine (DTaP-HBV-IPV/Hib) can further reduce the number of injections in pediatric immunization schedules of countries
Externí odkaz:
https://doaj.org/article/1776b521af0141ba8aeb3bf2c2968671
Autor:
Nicola P. Klein, Remon Abu-Elyazeed, Yaela Baine, Brigitte Cheuvart, Marcela Silerova, Narcisa Mesaros
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 2, Pp 327-338 (2019)
This phase III, open-label, randomized study (NCT01978093) evaluated the immunogenicity and safety of co-administered Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y–tetanus toxoid conjugate vaccine (Hib-MenCY-TT) with hum
Externí odkaz:
https://doaj.org/article/caf031fb117c49a692ba1fd070ce7e25
Autor:
Remon Abu-Elyazeed, William Jennings, Randall Severance, Michael Noss, Adrian Caplanusi, Michael Povey, Ouzama Henry
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 11, Pp 2624-2631 (2018)
The introduction of vaccination programs against measles, mumps, and rubella (MMR) led to significant global reduction in morbidity and mortality from these diseases. The currently recommended MMR vaccination schedule in the United States of America
Externí odkaz:
https://doaj.org/article/632bc8e2ad7849208d22446948c76815
Autor:
Veena Hoffman, Remon Abu-Elyazeed, Cheryl Enger, Daina B. Esposito, Michael C. Doherty, Scott C. Quinlan, Kathleen Skerry, Crystal N. Holick, Peter Basile, Leonard R. Friedland, Nicolas Praet, Stéphanie Wéry, Corinne Willame, David D. Dore, Dominique Rosillon
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 7, Pp 1782-1790 (2018)
As part of a regulatory commitment for post-licensure safety monitoring of live, oral human rotavirus vaccine (RV1), this study compared the incidence rates (IR) of intussusception, acute lower respiratory tract infection (LRTI) hospitalization, Kawa
Externí odkaz:
https://doaj.org/article/fd62db0cd2c14cfb95d4cddea76b6f3e
Autor:
Andrea A. Berry, Remon Abu-Elyazeed, Clemente Diaz-Perez, Maurice A. Mufson, Christopher J. Harrison, Michael Leonardi, Jerry D. Twiggs, Christopher Peltier, Stanley Grogg, Antonio Carbayo, Steven Shapiro, Michael Povey, Carmen Baccarini, Bruce L. Innis, Ouzama Henry
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 7, Pp 1516-1522 (2017)
One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA
Externí odkaz:
https://doaj.org/article/30e7337c65194fa8bf1cdd36c9885fa9
Publikováno v:
Open Forum Infectious Diseases. 9
Background GSK’s measles-mumps-rubella (MMR) vaccine is indicated for active immunization of individuals aged 12 months and older against these 3 serious illnesses. It is licensed in > 100 countries worldwide not including the US. In clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8eb703aaa6c7cb359cd7af0cc28dff99
https://doi.org/10.1093/ofid/ofac492.624
https://doi.org/10.1093/ofid/ofac492.624
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
A systematic literature review of Medline and Embase databases was conducted to describe rotavirus (RV) vaccine coverage for a complete series, timing of receipt of all doses in the series, and predictors of RV vaccination coverage in the US for two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2128bfac6f79830e76527c29d9973a2b
https://doi.org/10.1080/21645515.2020.1794440
https://doi.org/10.1080/21645515.2020.1794440
Autor:
R Leon Ochiai, Camilo J Acosta, M Carolina Danovaro-Holliday, Dong Baiqing, Sujit K Bhattacharya, Magdarina D Agtini, Zulfiqar A Bhutta, Do Gia Canh, Mohammad Ali, Seonghye Shin, John Wain, Anne-Laure Page, M John Albert, Jeremy Farrar, Remon Abu-Elyazeed, Tikki Pang, Claudia M Galindo, Lorenz von Seidlein, John D Clemens
Publikováno v:
Bulletin of the World Health Organization, Vol 86, Iss 4, Pp 260-268 (2008)
OBJECTIVE: To inform policy-makers about introduction of preventive interventions against typhoid, including vaccination. METHODS: A population-based prospective surveillance design was used. Study sites where typhoid was considered a problem by loca
Externí odkaz:
https://doaj.org/article/c74f58b0e8c649d7ae47aae437ce8b99